Natco Pharma to enhance total investment in eGenesis to $25 million
Natco positioning itself in multiplex gene-editing and genome-engineering platform | Photo Credit: The Hindu Natco Pharma is deepening its investment in clinical-stage biotechnology company eGenesis, increasing its planned investment through subsidiaries to $16.7 million from the earlier announced $14 million. Under the revised investment plan, Natco Pharma’s Canadian subsidiary will invest $13.7 million, while Natco…
Read More “Natco Pharma to enhance total investment in eGenesis to $25 million” »
